Nucleocytoplasmic transport of the RNA-binding protein CELF2 regulates neural stem cell fates.

CELF2 RNA-binding proteins cell fate decision cortical development neural stem cells neurodevelopmental disorder neurogenesis nucleocytoplasmic translocation rare disease translational repression

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
08 06 2021
Historique:
received: 16 11 2020
revised: 23 03 2021
accepted: 13 05 2021
entrez: 9 6 2021
pubmed: 10 6 2021
medline: 10 2 2022
Statut: ppublish

Résumé

The development of the cerebral cortex requires balanced expansion and differentiation of neural stem/progenitor cells (NPCs), which rely on precise regulation of gene expression. Because NPCs often exhibit transcriptional priming of cell-fate-determination genes, the ultimate output of these genes for fate decisions must be carefully controlled in a timely fashion at the post-transcriptional level, but how that is achieved is poorly understood. Here, we report that de novo missense variants in an RNA-binding protein CELF2 cause human cortical malformations and perturb NPC fate decisions in mice by disrupting CELF2 nucleocytoplasmic transport. In self-renewing NPCs, CELF2 resides in the cytoplasm, where it represses mRNAs encoding cell fate regulators and neurodevelopmental disorder-related factors. The translocation of CELF2 into the nucleus releases mRNA for translation and thereby triggers NPC differentiation. Our results reveal that CELF2 translocation between subcellular compartments orchestrates mRNA at the translational level to instruct cell fates in cortical development.

Identifiants

pubmed: 34107259
pii: S2211-1247(21)00577-5
doi: 10.1016/j.celrep.2021.109226
pii:
doi:

Substances chimiques

CELF Proteins 0
CELF2 protein, human 0
Nerve Tissue Proteins 0
RNA-Binding Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109226

Subventions

Organisme : CIHR
ID : PJT-165821
Pays : Canada

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests M.M. is employed by Blueprint Genetics. L.M. has received personal fees from Mendelian Ltd outside the submitted work. The other authors declare no competing interests.

Auteurs

Melissa J MacPherson (MJ)

Department of Medial Genetics, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada; Alberta Children's Hospital Research Institute, Calgary, AB T2N 4N1, Canada; Department of Medical Genetics, University of Alberta, Edmonton, AB T6G 2H7, Canada.

Sarah L Erickson (SL)

Department of Medial Genetics, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada; Alberta Children's Hospital Research Institute, Calgary, AB T2N 4N1, Canada.

Drayden Kopp (D)

Alberta Children's Hospital Research Institute, Calgary, AB T2N 4N1, Canada; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.

Pengqiang Wen (P)

Alberta Children's Hospital Research Institute, Calgary, AB T2N 4N1, Canada; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.

Mohamad-Reza Aghanoori (MR)

Department of Medial Genetics, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada; Alberta Children's Hospital Research Institute, Calgary, AB T2N 4N1, Canada.

Shreeya Kedia (S)

Alberta Children's Hospital Research Institute, Calgary, AB T2N 4N1, Canada; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.

Kaylan M L Burns (KML)

Alberta Children's Hospital Research Institute, Calgary, AB T2N 4N1, Canada; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.

Antonio Vitobello (A)

UFR Des Sciences de Santé, INSERM-Université de Bourgogne UMR1231 GAD Génétique des Anomalies du Développement, FHU-TRANSLAD, Dijon, France; Unité Fonctionnelle d'Innovation diagnostique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.

Frederic Tran Mau-Them (F)

UFR Des Sciences de Santé, INSERM-Université de Bourgogne UMR1231 GAD Génétique des Anomalies du Développement, FHU-TRANSLAD, Dijon, France; Unité Fonctionnelle d'Innovation diagnostique des maladies rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.

Quentin Thomas (Q)

UFR Des Sciences de Santé, INSERM-Université de Bourgogne UMR1231 GAD Génétique des Anomalies du Développement, FHU-TRANSLAD, Dijon, France; Centre de Génétique, Hôpital d'Enfants, CHU, 14 rue Paul Gaffarel, BP 77908, 21079 Dijon Cedex, France.

Nina B Gold (NB)

Division of Medical Genetics and Metabolism, Massachusetts General Hospital, Boston, MA 02115, USA; Harvard Medical School, Department of Pediatrics, Boston, MA, USA.

William Brucker (W)

Division of Genetics and Genomics 300 Longwood Avenue, Boston Children's Hospital, Boston, MA 02115, USA.

Louise Amlie-Wolf (L)

Nemours/Alfred I. duPont Hospital for Children, 1600 Rockland Road, Wilmington, DE 19803, USA.

Karen W Gripp (KW)

Nemours/Alfred I. duPont Hospital for Children, 1600 Rockland Road, Wilmington, DE 19803, USA.

Olaf Bodamer (O)

Division of Genetics and Genomics 300 Longwood Avenue, Boston Children's Hospital, Boston, MA 02115, USA.

Laurence Faivre (L)

UFR Des Sciences de Santé, INSERM-Université de Bourgogne UMR1231 GAD Génétique des Anomalies du Développement, FHU-TRANSLAD, Dijon, France; Centre de Génétique, Hôpital d'Enfants, CHU, 14 rue Paul Gaffarel, BP 77908, 21079 Dijon Cedex, France.

Mikko Muona (M)

Blueprint Genetics, Espoo, Finland; Folkhälsan Research Center, Helsinki, Finland.

Lara Menzies (L)

Department of Clinical Genetics, Great Ormond Street Hospital, London, UK.

Julia Baptista (J)

Exeter Genomics Laboratory, Royal Devon and Exeter NHS Hospital, Exeter, UK; College of Medicine and Health, University of Exeter, Exeter, UK.

Katie Guegan (K)

Exeter Genomics Laboratory, Royal Devon and Exeter NHS Hospital, Exeter, UK.

Alison Male (A)

Department of Clinical Genetics, Great Ormond Street Hospital, London, UK.

Xing-Chang Wei (XC)

Diagnostic Imaging, Alberta Children's Hospital, 28 Oki Drive NW, Calgary, AB T3B 6A8, Canada.

Guiqiong He (G)

Institute of Neuroscience, Chongqing Medical University, Chongqing 400016, China.

Quan Long (Q)

Department of Medial Genetics, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada; Alberta Children's Hospital Research Institute, Calgary, AB T2N 4N1, Canada; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.

A Micheil Innes (AM)

Department of Medial Genetics, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada; Alberta Children's Hospital Research Institute, Calgary, AB T2N 4N1, Canada. Electronic address: micheil.innes@albertahealthservices.ca.

Guang Yang (G)

Department of Medial Genetics, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada; Alberta Children's Hospital Research Institute, Calgary, AB T2N 4N1, Canada; Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada. Electronic address: guang.yang2@ucalgary.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH